Three Biotech Stocks to Buy When the Market Crashes

Gilead Sciences (NASDAQ:GILD), Celgene Corp. (NASDAQ:CELG), and Regeneron Pharmaceuticals (NASDAQ:REGN) aren't immune to market whims and whispers, but they do share one thing in common; a track record for developing multibillion dollar blockbuster drugs. Given that the NASDAQ Biotechnology ETF (NASDAQ:IBB) has plummeted 26.7% this year, is now a good time to buy shares in these industry titans? Read on to find out why I think adding them to your portfolio may be a profit-friendly move.

Back to news